Earnings ·
Lantern Pharma Inc. reported financial results for the second quarter ended June 30, 2026, announcing a net loss of…
LTRNLantern Pharma Inc.
Lantern Pharma Inc. reported financial results for the second quarter ended June 30, 2026, announcing a net loss of $7.1 million ($0.57 per share) and an operating loss of $3.5 million, which decreased approximately 25% year over year. The company holds $7.4 million in cash and marketable securities following a registered direct offering that raised $4.4 million in May 2026. Clinically, the HARMONIC trial for LP-300 showed median progression-free survival of 8.9 months in EGFR exon 21 L858R patients completing six cycles, prompting FDA-reviewed protocol amendments to focus enrollment on this subgroup and extend treatment to eight cycles. The EMA cleared an investigator-initiated Phase 1b/2 trial for LP-184 (zirdafulven) in biomarker-selected bladder cancer, while the USPTO issued a Notice of Allowance for a three-gene expression signature patent for LP-184. Additionally, Lantern established Open Medicine AI as a separate wholly-owned subsidiary with executed commercial licensing agreements.